https://scholars.lib.ntu.edu.tw/handle/123456789/191347
標題: | Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group | 作者: | Kim, Seok Jin Moon, Joon Ho Kim, Hawk Kim, Jin Seok Hwang, Yu Yan Intragumtornchai, Tanin Issaragrisil, Surapol Kwak, Jae Yong Lee, Je Jung Won, Jong Ho Reksodiputro, Arry Harryanto Lim, Soon Thye ANN-LII CHENG Kim, Won Seog Kwong, Yok Lam |
關鍵字: | Alemtuzumab;infection;prophylaxis | 公開日期: | 2012 | 起(迄)頁: | 1515-1524 | 來源出版物: | Leukemia & Lymphoma | 摘要: | This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of frontline (n = 48) or salvage (n = 90) treatment, and as a part of the conditioning regimen for allogeneic stem cell transplant (n = 44). Reactivation of cytomegalovirus (66/182) and varicella zoster virus (25/182), and fungal infection (31/182) including invasive pulmonary aspergillosis, were the most common infectious complications in this retrospective analysis. Thus, we recommend routine prophylaxis with valganciclovir and itraconazole, especially when alemtuzumab is used in the conditioning regimen for allogeneic stem cell transplant. Pneumocystis jirovecii pneumonia (PJP) was found in four patients (3%, 4/122) receiving alemtuzumab as conditioning for stem cell transplant or salvage treatment. Three cases of hepatitis B virus reactivation were found in antigen-negative patients, and 16 cases of tuberculosis were observed. Infection is the major complication of alemtuzumab therapy, and these infectious complications are potentially severe and life-threatening. Based on our retrospective analysis, we have constructed a guideline for antimicrobial prophylaxis in Asian patients receiving alemtuzumab therapy. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/280012 | DOI: | 10.3109/10428194.2012.659735 | SDG/關鍵字: | aciclovir; alemtuzumab; cotrimoxazole; fluconazole; itraconazole; valaciclovir; valganciclovir; acute granulocytic leukemia; adolescent; adult; aged; allogeneic stem cell transplantation; antibiotic prophylaxis; aplastic anemia; article; Asian; child; chronic lymphatic leukemia; Cytomegalovirus; cytomegalovirus infection; drug dose comparison; female; Hepatitis B virus; herpes zoster; human; lung aspergillosis; major clinical study; male; mycobacteriosis; mycosis; myelodysplastic syndrome; Pneumocystis jiroveci; Pneumocystis pneumonia; priority journal; retrospective study; school child; side effect; T cell lymphoma; Varicella zoster virus; virus reactivation; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asia; Child; Cytomegalovirus Infections; Female; Herpes Zoster; Humans; Lymphoma; Male; Middle Aged; Mycoses; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。